The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
Press Release|Articles|February 24, 2026
Emmes Coordinates Groundbreaking Stem-Cell Ophthalmology Trial
Emmes and UC Davis Eye Center advanced the largest study to date of autologous CD34+ stem cell therapy for CRVO, with phase I/II results demonstrating safety and feasibility while laying the groundwork for future retinal vascular treatments.
Advertisement
Emmes – a full-service, global Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation – in collaboration with the UC Davis Eye Center, helped coordinate the largest study of its kind using autologous CD34+ stem cells to treat vision loss caused by central retinal vein occlusion (CRVO), a common and often debilitating retinal vascular disease.
CD34+ stem cells are naturally occurring repair cells found in bone marrow that play a key role in vascular healing. In this investigator-initiated study, sponsored by the National Eye Institute, cells were isolated from a patient’s own bone marrow and injected into the eye, with the goal of repairing damaged retinal blood vessels and improving visual function.
A recently completed randomized phase I/II
SOURCE: Emmes
Advertisement
Related to this article
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
In today’s ACT Brief, we examine why anti-kickback guidance and EHR-integrated trial matching must work together in community settings, why real-time trials depend on mature risk-based quality management, and how pharma is applying digital clones to predict outcomes.
The FDA’s RTCT initiative transmits predefined, clinically meaningful signals to regulators during active trials, so its value depends entirely on the maturity of sponsors’ upstream RBQM signal intelligence, KRIs, QTLs, and root-cause context, rather than on data speed.
In this video interview, Kent Thoelke, CEO of Paradigm Health, outlines why anti-kickback guidance and modern EHR-integrated trial matching technology must work in tandem to reach representative patient populations at the community level.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
Real-Time Continuous Trials Through the Lens of Risk-Based Quality Management: Why RBQM Is the Infrastructure RTCT Cannot Exist Without
3
What Needs to Happen Beyond the Clinical Trial Modernization Act
4
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
5